Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children
The combination of atovaquone and proguanil is highly effective and safe for the treatment of Plasmodium falciparum malaria. We aimed in this randomised, double-blind, placebo-controlled study to assess the efficacy and safety of this combination for malaria prophylaxis. 320 children who lived in a...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 1998-03, Vol.351 (9104), p.709-713 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 713 |
|---|---|
| container_issue | 9104 |
| container_start_page | 709 |
| container_title | The Lancet (British edition) |
| container_volume | 351 |
| creator | Lell, Bertrand Luckner, Doris Ndjavé, Maryse Scott, Trevor Kremsner, Peter G |
| description | The combination of atovaquone and proguanil is highly effective and safe for the treatment of
Plasmodium falciparum malaria. We aimed in this randomised, double-blind, placebo-controlled study to assess the efficacy and safety of this combination for malaria prophylaxis.
320 children who lived in a hyperendemic area for
P falciparum malaria were stratified by weight and randomly assigned atovaquone plus proguanil or placebo once daily for 12 weeks. All children received initial curative treatment with atovaquone and proguanil before the start of chemosuppression. We recorded adverse events daily and collected thick blood smears once a week. The primary endpoint was a positive blood smear.
25 of 140 children in the placebo group and none of the 125 children in the atovaquone plus proguanil group had positive smears during chemosuppression (p |
| doi_str_mv | 10.1016/S0140-6736(97)09222-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79726192</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673697092222</els_id><sourcerecordid>27073246</sourcerecordid><originalsourceid>FETCH-LOGICAL-c416t-9b450159459da4b81a49d5348fbfb60033f119f1bdb4086e250476deb806905a3</originalsourceid><addsrcrecordid>eNqFkVuLFDEQhYMo67j6ExYaEdGH1kp3ku48iSzeYEHwAr6FyqXdLJlkNulenH9vemeYB198Kqj6qjh1DiEXFN5QoOLtd6AMWjH04pUcXoPsuq7tHpANZQNrORt-PSSbE_KYPCnlBgCYAH5GziQHxinfEPsNo01bX5xtdgGN06k1Kc45hVBbZV7svklTg3O6w9slRVexpTS7nH4vGH1oppSbLQbMHtfu7nof8I8vjY-NufbBZhefkkcThuKeHes5-fnxw4_Lz-3V109fLt9ftYZRMbdSMw6US8alRaZHikxa3rNx0pMWAH0_USonqq1mMArX1ScGYZ0eQUjg2J-Tl4e7Vcft4sqs6mPGhYDRpaWoQQ6doLKr4PN_wJu05Fi1KSolUAnjCvEDZHIqJbtJ7bLfYt4rCmqNQN1HoFZ_lRzUfQRq3bs4Hl_01tnT1tHzOn9xnGMxGKaM0fhywjoqqJCiYu8OmKuO3XmXVTHeReOsz87Myib_HyF_AaLiowA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>199019082</pqid></control><display><type>article</type><title>Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children</title><source>MEDLINE</source><source>EBSCOhost Business Source Complete</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Lell, Bertrand ; Luckner, Doris ; Ndjavé, Maryse ; Scott, Trevor ; Kremsner, Peter G</creator><creatorcontrib>Lell, Bertrand ; Luckner, Doris ; Ndjavé, Maryse ; Scott, Trevor ; Kremsner, Peter G</creatorcontrib><description>The combination of atovaquone and proguanil is highly effective and safe for the treatment of
Plasmodium falciparum malaria. We aimed in this randomised, double-blind, placebo-controlled study to assess the efficacy and safety of this combination for malaria prophylaxis.
320 children who lived in a hyperendemic area for
P falciparum malaria were stratified by weight and randomly assigned atovaquone plus proguanil or placebo once daily for 12 weeks. All children received initial curative treatment with atovaquone and proguanil before the start of chemosuppression. We recorded adverse events daily and collected thick blood smears once a week. The primary endpoint was a positive blood smear.
25 of 140 children in the placebo group and none of the 125 children in the atovaquone plus proguanil group had positive smears during chemosuppression (p<0·001). Adverse events during the chemosuppression phase did not differ between the groups.
The combination of atovaquone plus proguanil is a highly effective and well-tolerated chemosuppressive antimalarial in children. This drug combination could replace current regimens.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(97)09222-2</identifier><identifier>PMID: 9504515</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Adolescent ; Antimalarials - administration & dosage ; Antimalarials - therapeutic use ; Atovaquone ; Biological and medical sciences ; Blood ; Child ; Child, Preschool ; Children & youth ; Cohort Studies ; Double-Blind Method ; Drug therapy ; Drug Therapy, Combination ; Human protozoal diseases ; Humans ; Infectious diseases ; Malaria ; Malaria - prevention & control ; Medical research ; Medical sciences ; Naphthoquinones - administration & dosage ; Naphthoquinones - therapeutic use ; Parasitic diseases ; Population ; Proguanil - administration & dosage ; Proguanil - therapeutic use ; Prophylaxis ; Protozoal diseases ; Tropical medicine ; Vector-borne diseases</subject><ispartof>The Lancet (British edition), 1998-03, Vol.351 (9104), p.709-713</ispartof><rights>1998 Elsevier Ltd</rights><rights>1998 INIST-CNRS</rights><rights>Copyright Lancet Ltd. Mar 7, 1998</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c416t-9b450159459da4b81a49d5348fbfb60033f119f1bdb4086e250476deb806905a3</citedby><cites>FETCH-LOGICAL-c416t-9b450159459da4b81a49d5348fbfb60033f119f1bdb4086e250476deb806905a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/199019082?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2161696$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9504515$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lell, Bertrand</creatorcontrib><creatorcontrib>Luckner, Doris</creatorcontrib><creatorcontrib>Ndjavé, Maryse</creatorcontrib><creatorcontrib>Scott, Trevor</creatorcontrib><creatorcontrib>Kremsner, Peter G</creatorcontrib><title>Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>The combination of atovaquone and proguanil is highly effective and safe for the treatment of
Plasmodium falciparum malaria. We aimed in this randomised, double-blind, placebo-controlled study to assess the efficacy and safety of this combination for malaria prophylaxis.
320 children who lived in a hyperendemic area for
P falciparum malaria were stratified by weight and randomly assigned atovaquone plus proguanil or placebo once daily for 12 weeks. All children received initial curative treatment with atovaquone and proguanil before the start of chemosuppression. We recorded adverse events daily and collected thick blood smears once a week. The primary endpoint was a positive blood smear.
25 of 140 children in the placebo group and none of the 125 children in the atovaquone plus proguanil group had positive smears during chemosuppression (p<0·001). Adverse events during the chemosuppression phase did not differ between the groups.
The combination of atovaquone plus proguanil is a highly effective and well-tolerated chemosuppressive antimalarial in children. This drug combination could replace current regimens.</description><subject>Adolescent</subject><subject>Antimalarials - administration & dosage</subject><subject>Antimalarials - therapeutic use</subject><subject>Atovaquone</subject><subject>Biological and medical sciences</subject><subject>Blood</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children & youth</subject><subject>Cohort Studies</subject><subject>Double-Blind Method</subject><subject>Drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Human protozoal diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Malaria</subject><subject>Malaria - prevention & control</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Naphthoquinones - administration & dosage</subject><subject>Naphthoquinones - therapeutic use</subject><subject>Parasitic diseases</subject><subject>Population</subject><subject>Proguanil - administration & dosage</subject><subject>Proguanil - therapeutic use</subject><subject>Prophylaxis</subject><subject>Protozoal diseases</subject><subject>Tropical medicine</subject><subject>Vector-borne diseases</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkVuLFDEQhYMo67j6ExYaEdGH1kp3ku48iSzeYEHwAr6FyqXdLJlkNulenH9vemeYB198Kqj6qjh1DiEXFN5QoOLtd6AMWjH04pUcXoPsuq7tHpANZQNrORt-PSSbE_KYPCnlBgCYAH5GziQHxinfEPsNo01bX5xtdgGN06k1Kc45hVBbZV7svklTg3O6w9slRVexpTS7nH4vGH1oppSbLQbMHtfu7nof8I8vjY-NufbBZhefkkcThuKeHes5-fnxw4_Lz-3V109fLt9ftYZRMbdSMw6US8alRaZHikxa3rNx0pMWAH0_USonqq1mMArX1ScGYZ0eQUjg2J-Tl4e7Vcft4sqs6mPGhYDRpaWoQQ6doLKr4PN_wJu05Fi1KSolUAnjCvEDZHIqJbtJ7bLfYt4rCmqNQN1HoFZ_lRzUfQRq3bs4Hl_01tnT1tHzOn9xnGMxGKaM0fhywjoqqJCiYu8OmKuO3XmXVTHeReOsz87Myib_HyF_AaLiowA</recordid><startdate>19980307</startdate><enddate>19980307</enddate><creator>Lell, Bertrand</creator><creator>Luckner, Doris</creator><creator>Ndjavé, Maryse</creator><creator>Scott, Trevor</creator><creator>Kremsner, Peter G</creator><general>Elsevier Ltd</general><general>Lancet</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>19980307</creationdate><title>Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children</title><author>Lell, Bertrand ; Luckner, Doris ; Ndjavé, Maryse ; Scott, Trevor ; Kremsner, Peter G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c416t-9b450159459da4b81a49d5348fbfb60033f119f1bdb4086e250476deb806905a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adolescent</topic><topic>Antimalarials - administration & dosage</topic><topic>Antimalarials - therapeutic use</topic><topic>Atovaquone</topic><topic>Biological and medical sciences</topic><topic>Blood</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children & youth</topic><topic>Cohort Studies</topic><topic>Double-Blind Method</topic><topic>Drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Human protozoal diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Malaria</topic><topic>Malaria - prevention & control</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Naphthoquinones - administration & dosage</topic><topic>Naphthoquinones - therapeutic use</topic><topic>Parasitic diseases</topic><topic>Population</topic><topic>Proguanil - administration & dosage</topic><topic>Proguanil - therapeutic use</topic><topic>Prophylaxis</topic><topic>Protozoal diseases</topic><topic>Tropical medicine</topic><topic>Vector-borne diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lell, Bertrand</creatorcontrib><creatorcontrib>Luckner, Doris</creatorcontrib><creatorcontrib>Ndjavé, Maryse</creatorcontrib><creatorcontrib>Scott, Trevor</creatorcontrib><creatorcontrib>Kremsner, Peter G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News & ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lell, Bertrand</au><au>Luckner, Doris</au><au>Ndjavé, Maryse</au><au>Scott, Trevor</au><au>Kremsner, Peter G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>1998-03-07</date><risdate>1998</risdate><volume>351</volume><issue>9104</issue><spage>709</spage><epage>713</epage><pages>709-713</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><coden>LANCAO</coden><abstract>The combination of atovaquone and proguanil is highly effective and safe for the treatment of
Plasmodium falciparum malaria. We aimed in this randomised, double-blind, placebo-controlled study to assess the efficacy and safety of this combination for malaria prophylaxis.
320 children who lived in a hyperendemic area for
P falciparum malaria were stratified by weight and randomly assigned atovaquone plus proguanil or placebo once daily for 12 weeks. All children received initial curative treatment with atovaquone and proguanil before the start of chemosuppression. We recorded adverse events daily and collected thick blood smears once a week. The primary endpoint was a positive blood smear.
25 of 140 children in the placebo group and none of the 125 children in the atovaquone plus proguanil group had positive smears during chemosuppression (p<0·001). Adverse events during the chemosuppression phase did not differ between the groups.
The combination of atovaquone plus proguanil is a highly effective and well-tolerated chemosuppressive antimalarial in children. This drug combination could replace current regimens.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><pmid>9504515</pmid><doi>10.1016/S0140-6736(97)09222-2</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 1998-03, Vol.351 (9104), p.709-713 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79726192 |
| source | MEDLINE; EBSCOhost Business Source Complete; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Adolescent Antimalarials - administration & dosage Antimalarials - therapeutic use Atovaquone Biological and medical sciences Blood Child Child, Preschool Children & youth Cohort Studies Double-Blind Method Drug therapy Drug Therapy, Combination Human protozoal diseases Humans Infectious diseases Malaria Malaria - prevention & control Medical research Medical sciences Naphthoquinones - administration & dosage Naphthoquinones - therapeutic use Parasitic diseases Population Proguanil - administration & dosage Proguanil - therapeutic use Prophylaxis Protozoal diseases Tropical medicine Vector-borne diseases |
| title | Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T18%3A45%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Randomised%20placebo-controlled%20study%20of%20atovaquone%20plus%20proguanil%20for%20malaria%20prophylaxis%20in%20children&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Lell,%20Bertrand&rft.date=1998-03-07&rft.volume=351&rft.issue=9104&rft.spage=709&rft.epage=713&rft.pages=709-713&rft.issn=0140-6736&rft.eissn=1474-547X&rft.coden=LANCAO&rft_id=info:doi/10.1016/S0140-6736(97)09222-2&rft_dat=%3Cproquest_cross%3E27073246%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=199019082&rft_id=info:pmid/9504515&rft_els_id=S0140673697092222&rfr_iscdi=true |